305 related articles for article (PubMed ID: 32990678)
1. MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation.
Fang Y; Wang L; Wan C; Sun Y; Van der Jeught K; Zhou Z; Dong T; So KM; Yu T; Li Y; Eyvani H; Colter AB; Dong E; Cao S; Wang J; Schneider BP; Sandusky GE; Liu Y; Zhang C; Lu X; Zhang X
J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 32990678
[TBL] [Abstract][Full Text] [Related]
2. Immune MAL2-practice: breast cancer immunoevasion via MHC class I degradation.
Dersh D; Yewdell JW
J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33393509
[TBL] [Abstract][Full Text] [Related]
3. Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation.
Xu H; Van der Jeught K; Zhou Z; Zhang L; Yu T; Sun Y; Li Y; Wan C; So KM; Liu D; Frieden M; Fang Y; Mosley AL; He X; Zhang X; Sandusky GE; Liu Y; Meroueh SO; Zhang C; Wijeratne AB; Huang C; Ji G; Lu X
J Clin Invest; 2021 May; 131(10):. PubMed ID: 33830945
[TBL] [Abstract][Full Text] [Related]
4. Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression.
Kriegsman BA; Vangala P; Chen BJ; Meraner P; Brass AL; Garber M; Rock KL
J Immunol; 2019 Oct; 203(7):1999-2010. PubMed ID: 31471524
[TBL] [Abstract][Full Text] [Related]
5. Antigen processing and immune regulation in the response to tumours.
Reeves E; James E
Immunology; 2017 Jan; 150(1):16-24. PubMed ID: 27658710
[TBL] [Abstract][Full Text] [Related]
6. NLRC5/MHC class I transactivator is a target for immune evasion in cancer.
Yoshihama S; Roszik J; Downs I; Meissner TB; Vijayan S; Chapuy B; Sidiq T; Shipp MA; Lizee GA; Kobayashi KS
Proc Natl Acad Sci U S A; 2016 May; 113(21):5999-6004. PubMed ID: 27162338
[TBL] [Abstract][Full Text] [Related]
7. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
Front Immunol; 2019; 10():1505. PubMed ID: 31333652
[TBL] [Abstract][Full Text] [Related]
8. COPS6 promotes tumor progression and reduces CD8
Du WQ; Zhu ZM; Jiang X; Kang MJ; Pei DS
Acta Pharmacol Sin; 2023 Sep; 44(9):1890-1905. PubMed ID: 37095198
[TBL] [Abstract][Full Text] [Related]
9. Activation of MAL2 by RAD21 inhibits the expression of MHC-I in immune evasion of endometrial cancer.
Jin Y; Lu X; Liu Y; Su L; Bao C; Guo H
Cytotechnology; 2024 Aug; 76(4):465-482. PubMed ID: 38933871
[TBL] [Abstract][Full Text] [Related]
10. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion.
Jhunjhunwala S; Hammer C; Delamarre L
Nat Rev Cancer; 2021 May; 21(5):298-312. PubMed ID: 33750922
[TBL] [Abstract][Full Text] [Related]
11. Whole protein and defined CD8(+) and CD4(+) peptides linked to penetratin targets both MHC class I and II antigen presentation pathways.
Pouniotis DS; Esparon S; Apostolopoulos V; Pietersz GA
Immunol Cell Biol; 2011 Nov; 89(8):904-13. PubMed ID: 21383765
[TBL] [Abstract][Full Text] [Related]
12. Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.
Dhatchinamoorthy K; Colbert JD; Rock KL
Front Immunol; 2021; 12():636568. PubMed ID: 33767702
[TBL] [Abstract][Full Text] [Related]
13. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.
Jackaman C; Bundell CS; Kinnear BF; Smith AM; Filion P; van Hagen D; Robinson BW; Nelson DJ
J Immunol; 2003 Nov; 171(10):5051-63. PubMed ID: 14607902
[TBL] [Abstract][Full Text] [Related]
14. Development of a Human Cytomegalovirus (HCMV)-Based Therapeutic Cancer Vaccine Uncovers a Previously Unsuspected Viral Block of MHC Class I Antigen Presentation.
Abdelaziz MO; Ossmann S; Kaufmann AM; Leitner J; Steinberger P; Willimsky G; Raftery MJ; Schönrich G
Front Immunol; 2019; 10():1776. PubMed ID: 31417555
[TBL] [Abstract][Full Text] [Related]
15. Efficient Uptake of Recombinant Lipidated Survivin by Antigen-Presenting Cells Initiates Antigen Cross-Presentation and Antitumor Immunity.
Chiang CY; Chen YJ; Wu CC; Liu SJ; Leng CH; Chen HW
Front Immunol; 2018; 9():822. PubMed ID: 29755461
[TBL] [Abstract][Full Text] [Related]
16. Cognate interactions between memory T cells and tumor antigen-presenting dendritic cells from bone marrow of breast cancer patients: bidirectional cell stimulation, survival and antitumor activity in vivo.
Bai L; Beckhove P; Feuerer M; Umansky V; Choi C; Solomayer FS; Diel IJ; Schirrmacher V
Int J Cancer; 2003 Jan; 103(1):73-83. PubMed ID: 12455056
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen.
Sharabi AB; Nirschl CJ; Kochel CM; Nirschl TR; Francica BJ; Velarde E; Deweese TL; Drake CG
Cancer Immunol Res; 2015 Apr; 3(4):345-55. PubMed ID: 25527358
[TBL] [Abstract][Full Text] [Related]
18. CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer.
Nielsen JS; Sahota RA; Milne K; Kost SE; Nesslinger NJ; Watson PH; Nelson BH
Clin Cancer Res; 2012 Jun; 18(12):3281-92. PubMed ID: 22553348
[TBL] [Abstract][Full Text] [Related]
19. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
[TBL] [Abstract][Full Text] [Related]
20. MHC class I TCR engineered anti-tumor CD4 T cells: implications for cancer immunotherapy.
Chhabra A
Endocr Metab Immune Disord Drug Targets; 2009 Dec; 9(4):344-52. PubMed ID: 19807670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
